Publications

5803 Results

Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial

Authors
M Othus;S Patel;YK Chae;E Deitrich;H Streicher;E Sharon;R Kurzrock
Journal / Conference
JNCI-Journal of the National Cancer Institute May 8;116(5):673-680
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID38243705
PMC
PMC11077308
Study Number(s)
S1609

Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial

Authors
J Ligibel;K Ballman;L McCall;P Goodwin;A Weiss;T Crane;M Irwin;C Thomson;O Hahn;P Spears;D Hershman;E Paskett;J Hopkins;V Bernstein;V Stearns;J White;T Wadden;E Winer;L Carey;A Partridge
Journal / Conference
ESMO (September 13-17, 2024, Barcelona, Spain), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
CTSU/A011401

Beyond Involved-Site Radiotherapy: NRG, COG, ALLIANCE, ECOG, SWOG, and CCTG Consensus Nomenclature for Radiation Targets on NCTN Lymphoma Trials

Authors
O Saifi;C Pinnix;L Ballas;C Kelsey;S Milgrom;S Terezakis;N Figura;R Parikh;J Grecula;J Plastaras;D Hodgson;B Hoppe
Journal / Conference
ASTRO Annual Meeting (September 29 - October 2, 2024, Washington, DC), Quick Pitch Oral Presention; International Journal of Radiation Oncology, Biology, Physics Volume 120:Number 2S
Year
2024
Research Committee(s)
Lymphoma

Evaluation of a prognostic scoring system among patients in the Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction Study (SWOG 1316)

Authors
C Watson;K Arnold;R Krouse;G Anderson;J Deneve;G Deutsch;B Davidson;A Secord
Journal / Conference
IGCS Meeting (October 16-18, 2024 Dublin, Ire), poster
Year
2024
Research Committee(s)
Palliative Care
Study Number(s)
S1316

Utilization of genomic tumor testing (GTT) among community oncologists participating in SWOG S2108CD

Authors
M Trivedi;A Michel;J Unger;S Colby;L Graham;K Reed;J Fischer;B Symington;S Ramsey;D Hershman;J Rueter
Journal / Conference
ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), poster;JCO Oncol Pract 20, 2024 (suppl 10; abstr 320)
Year
2024
Research Committee(s)
Cancer Care Delivery
Study Number(s)
S2108CD

The Cost of Doing Business – Drug Costs in Federally-Sponsored Cancer Clinical Trials

Authors
J Unger;H Xiao;R Vaidya;S Threlkel;M Chansky;A Hayes;D Hershman;M LeBlanc
Journal / Conference
ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), poster; JCO Oncol Pract 20, 2024 (suppl 10; abstr 10)
Year
2024
Research Committee(s)
Cancer Care Delivery

Correlations Between Baseline Tumor Burden and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)

Authors
P Swiecicki;M Othus;S Patel;Y Chae;R Kurzrock
Journal / Conference
SITC (Nov. 6-10, Houston, TX), poster
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

Authors
S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;S Parsons;F Keller;R Drachtman;A Lambert;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;R Little;M Smith;H Dillon;J Song;S Smith;J Friedberg;K Kelly
Journal / Conference
ISHL (October 26-28, Cologne, Germany), oral
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients (aged =60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826

Authors
S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens
Journal / Conference
ISHL (October 26-28, Cologne, Germany), oral
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial

Authors
J Boughey;V Suman;K Hunt;B Haffty;T Buchholz;F Symmons;T Rieken;T Dockter;J Campbell;J Bradley;J Mammen;A Partridge;L Carey
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
CTSU/A011202